UK indapamide market is estimated to grow significantly at a CAGR of around 2.4% during the forecast period. A significant prevalence of CVDs has been witnessed in the country. According to the British Heart Foundation, more than one-fourth of the fatalities in UK occur due to CVDs, and it is responsible for around 1.6 million fatalities each year. Moreover, more than 7 million people live with one or the other type of heart diseases in UK in 2018. The rise in the aging population is increasing the prevalence rate of CVDs including stroke and other heart diseases. As per the Institute for Health Metrics and Evaluation, around 107,000 new cases of stroke were registered in the country in 2017. According to NHS, the cost incurred to the patients for the treatment of stroke is around $3.8 billion each year and a loss of $5.1 billion due to loss of productivity, disability, and informal care. Therefore, the increasing burden of stroke further raises the demand for indapamide for the preventive treatment in the country that further propels the market growth.
Get Free Sample link @ https://www.omrglobal.com/request-sample/uk-indapamide-market
The UK indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
A full report of UK Indapamide Market available @ https://www.omrglobal.com/industry-reports/uk-indapamide-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
UK Indapamide Market by Product
- 25 MG
- 5 MG
UK Indapamide Market by Application
- High Blood Pressure
- Heart Failure
- Others
Company Profiles
- Bioindustria L.I.M. S.p.A.
- Grupo Azevedos
- Krka Group
- Laboratori Baldacci S.p.A.
- Merck KGaA
- Mylan N.V.
- Sandoz International GmbH
- Sanofi S.A.
- Servier Group
- Teva Pharmaceuticals Industries Ltd.
The Report Covers
- Comprehensive research methodology of the UK indapamide market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the UK indapamide market.
- Insights about market determinants which are stimulating the UK indapamide market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-indapamide-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
